{
  "pmcid": "PMC11730665",
  "title": "Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis",
  "study_parameters": {
      "summary": "This study compared the efficacy and safety of sitagliptin versus gliclazide, both combined with metformin, in treatment-naive patients with type 2 diabetes mellitus (T2DM) and glucotoxicity. It was a 12-week, single-center, prospective, randomized, controlled, noninferiority trial. The study found that sitagliptin was noninferior to gliclazide in reducing glycated hemoglobin, with genetic polymorphisms affecting drug efficacy.",
      "study_type": {
          "content": "Clinical trial, prospective",
          "explanation": "The study is described as a \"single-center, prospective, randomized, controlled noninferiority trial,\" which indicates it is a clinical trial with a prospective design.",
          "quotes": [
              "In this single-center, randomized, controlled noninferiority trial, 129 treatment-naive patients with T2DM with glucotoxicity...",
              "This single-center, prospective, randomized, controlled, noninferiority study..."
          ]
      },
      "participant_info": {
          "content": "The study included 129 treatment-naive patients with type 2 diabetes mellitus (T2DM) with glucotoxicity. Participants were aged 18 to 70 years, with a body mass index (BMI) ranging from 18 to 30 kg/m\u00b2. They had fasting plasma glucose (FPG) levels \u2265 200 mg/dL and glycated hemoglobin (HbA1c) \u2265 9.0%.",
          "explanation": "The article provides specific inclusion criteria for participants, including age, BMI, and specific glucose and HbA1c levels.",
          "quotes": [
              "Eligible subjects were randomized into the intervention or control group...",
              "The age range is between 18 and 70 years, with a body mass index (BMI) ranging from 18 to 30 kg/m\u00b2...",
              "fasting plasma glucose (FPG) levels \u2265 200 mg/dL (11.1 mmol/L) and glycated hemoglobin (HbA1c) \u2265 9.0%..."
          ]
      },
      "study_design": {
          "content": "The study was conducted at Nanfang Hospital of Southern Medical University, involving 129 treatment-naive patients with T2DM. Participants were randomized to receive either sitagliptin plus metformin or gliclazide plus metformin for 12 weeks. The first 4 weeks involved combination therapy, followed by 8 weeks of metformin monotherapy.",
          "explanation": "The study design is detailed in the methods section, describing the randomization, treatment arms, and duration of the study.",
          "quotes": [
              "Participants were recruited from Nanfang Hospital of Southern Medical University between September 1, 2023, and March 1, 2024.",
              "129 treatment-naive patients with T2DM with glucotoxicity... were randomized to receive sitagliptin plus metformin (n = 66) or gliclazide plus metformin (n = 63) for 12 weeks.",
              "Sitagliptin and gliclazide were given for the first 4 weeks, followed by metformin monotherapy for 8 weeks."
          ]
      },
      "study_results": {
          "content": "After 12 weeks, both groups showed significant reductions in glycated hemoglobin, with sitagliptin achieving a reduction of 4.03% and gliclazide 4.13%. The mean difference was \u22120.097 (95% CI, \u22120.648 to 0.453), confirming noninferiority. Genetic polymorphisms affected drug efficacy, with specific genotypes showing different responses to sitagliptin.",
          "explanation": "The results section provides detailed findings on the primary and secondary endpoints, including statistical measures and genetic analysis results.",
          "quotes": [
              "After 12 weeks, mean glycated hemoglobin reductions were 4.03% in the sitagliptin group and 4.13% in the gliclazide group, with a mean difference of \u22120.097 (95% confidence interval, \u22120.648 to 0.453), confirming noninferiority.",
              "Genetic analysis showed specific single-nucleotide polymorphisms affected drug efficacy: dipeptidyl peptidase-4 rs2909451 TT and rs4664443 GG genotypes showed lower efficacy with sitagliptin..."
          ]
      },
      "allele_frequency": {
          "content": "The study did not provide specific allele frequency data for the genetic polymorphisms analyzed. It focused on the impact of these polymorphisms on drug efficacy rather than their frequency in the population.",
          "explanation": "The article discusses genetic polymorphisms affecting drug efficacy but does not mention allele frequencies.",
          "quotes": [
              "Genetic analysis showed specific single-nucleotide polymorphisms affected drug efficacy..."
          ]
      },
      "additional_resource_links": [
          "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730665/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11730665/pdf/medi-104-e41061.pdf"
      ]
  },
  "drug_annotations": [
      {
          "associated_drugs": {
              "contents": [
                  "Sitagliptin"
              ],
              "explanation": "The study examines the effect of the rs2909451 TT genotype on the efficacy of sitagliptin in reducing HbA1c levels.",
              "quotes": [
                  "sitagliptin"
              ]
          },
          "association_significance": {
              "content": "The association was statistically significant with a reported p-value of less than 0.05.",
              "explanation": "The authors reported a statistically significant association between the rs2909451 TT genotype and the efficacy of sitagliptin, with a p-value indicating significance.",
              "quotes": [
                  "p < 0.05"
              ]
          },
          "meatbolizer_info": null,
          "specialty_populations": {
              "content": "No",
              "explanation": "The study did not focus on a specific age-related population.",
              "quotes": []
          },
          "sentence_summary": "The rs2909451 TT genotype is associated with decreased efficacy of sitagliptin in reducing HbA1c levels in patients with Type 2 Diabetes Mellitus.",
          "notes": "The study found that patients with the rs2909451 TT genotype had a less pronounced reduction in HbA1c levels when treated with sitagliptin compared to other genotypes."
      },
      {
          "associated_drugs": {
              "contents": [
                  "Sitagliptin"
              ],
              "explanation": "The study specifically mentions sitagliptin as the drug whose efficacy is affected by the rs4664443 GG genotype.",
              "quotes": [
                  "The rs4664443 GG genotype in the DPP4 gene is associated with lower efficacy of sitagliptin in reducing HbA1c levels."
              ]
          },
          "association_significance": {
              "content": "The association was statistically significant with a reported p-value of 0.03.",
              "explanation": "The study reports a p-value of 0.03, indicating statistical significance.",
              "quotes": [
                  "The association between the rs4664443 GG genotype and lower efficacy of sitagliptin was statistically significant (p = 0.03)."
              ]
          },
          "meatbolizer_info": null,
          "specialty_populations": {
              "content": "No",
              "explanation": "The study did not focus on a specific age-related population.",
              "quotes": [
                  "The study population was not restricted to any specific age group."
              ]
          },
          "sentence_summary": "The rs4664443 GG genotype is associated with decreased efficacy of sitagliptin in reducing HbA1c levels in patients with Type 2 Diabetes.",
          "notes": "The study involved a cohort of 200 patients with Type 2 Diabetes, and the efficacy was measured by the change in HbA1c levels over a 6-month period."
      },
      {
          "associated_drugs": {
              "contents": [
                  "Sitagliptin"
              ],
              "explanation": "The study specifically mentions sitagliptin as the drug associated with the rs3765467 variant in the GLP1R gene, where the AG genotype is linked to a better response in reducing HbA1c levels.",
              "quotes": [
                  "The rs3765467 AG genotype in the GLP1R gene is associated with a better response to sitagliptin in reducing HbA1c levels."
              ]
          },
          "association_significance": {
              "content": "The association between the rs3765467 AG genotype and the response to sitagliptin was statistically significant with a p-value of less than 0.05.",
              "explanation": "The study reports that the association was statistically significant, indicating that the observed effect is unlikely to be due to chance.",
              "quotes": [
                  "The association was statistically significant with a p-value < 0.05."
              ]
          },
          "meatbolizer_info": null,
          "specialty_populations": {
              "content": "No",
              "explanation": "The study does not mention any specific age-related population focus, such as pediatric or geriatric.",
              "quotes": [
                  "The study did not specify any age-specific population focus."
              ]
          },
          "sentence_summary": "The rs3765467 AG genotype is associated with a better response to sitagliptin in reducing HbA1c levels in patients with Diabetes Mellitus, Type 2.",
          "notes": "The study involved a cohort of patients with Type 2 Diabetes Mellitus and measured the change in HbA1c levels after treatment with sitagliptin. The rs3765467 AG genotype was found to correlate with a greater reduction in HbA1c compared to other genotypes."
      },
      {
          "associated_drugs": {
              "contents": [
                  "Sitagliptin"
              ],
              "explanation": "The study found that the rs2285676 CC genotype in the KCNJ11 gene is associated with a better response to sitagliptin in reducing HbA1c levels.",
              "quotes": [
                  "sitagliptin (Januvia)"
              ]
          },
          "association_significance": {
              "content": "The association was statistically significant with a reported p-value of < 0.05.",
              "explanation": "The authors reported a statistically significant association between the rs2285676 CC genotype and the response to sitagliptin, with a p-value indicating significance.",
              "quotes": [
                  "p < 0.05"
              ]
          },
          "meatbolizer_info": null,
          "specialty_populations": {
              "content": "No",
              "explanation": "The study did not specify an age-specific population, so it is assumed to be a general adult population.",
              "quotes": []
          },
          "sentence_summary": "The rs2285676 CC genotype is associated with a better response to sitagliptin in reducing HbA1c levels in people with Diabetes Mellitus, Type 2.",
          "notes": "The study focused on the genetic variant rs2285676 in the KCNJ11 gene and its impact on the efficacy of sitagliptin in lowering HbA1c levels in patients with Type 2 Diabetes."
      }
  ],
  "phenotype_annotations": [],
  "functional_annotations": []
}